Actual 5-Year Survival of Patients with Stage IIIB Breast Carcinoma: Phase II Trial of Methotrexate, Vinblastine, Adriamycin, Cisplatin, and Folinic Acid

References

• Hortobagyi G N, Singletary S E, McNeese M D. Treatment of locally advanced and inflammatory breast cancer. Diseases of the Breast, ME Lippman, M Marrow, S Hellman. Lippincott-Raven, Philadelphia 1996; 585–599
   Google Scholar
• DeLena M, Zucali R, Viganotti G. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chem Pharm 1978; 1: 53–59
   PubMed Web of Science ®Google Scholar
• Hortobagyi G N, Blumenschein G R, Spanos W. Multimodal treatment of locoregionally advanced breast cancer. Cancer 1983; 51: 763–768
   PubMed Web of Science ®Google Scholar
• Sledge GW, Jr, Loehrer P J, Roth B J. Cisplatin as first-line therapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1987; 6: 206
   Google Scholar
• Kolaric K, Vukas D, Roth A. Cyclopbosphamide, adriamycin and platinum (CAP) combination chemotherapy, a new effective approach in the treatment of disseminated breast cancer. Preliminary report. Tumori 1985; 71: 159–165
   PubMed Web of Science ®Google Scholar
• Cocconi G, Bisagni G, Bacchi M. Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1991; 9: 664–669
   PubMed Web of Science ®Google Scholar
• Sternberg C N, Yagoda A, Scher H I. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985; 133: 403–407
   PubMed Web of Science ®Google Scholar
• DeLena M, Varini M, Zucoli R. Multimodal treatment for locally advanced breast cancer. Result of chemotherapy radiotherapy versus chemotherapy-surgery. Cancer Clin Trials 1981; 4: 229–236
   PubMedGoogle Scholar
• Hortobagyi G N, Ames F C, Buzdar A U. Management of stage III primary breast cancer with primary chemotherapy surgery, and radiation therapy. Cancer 1988; 62: 2507–2516
   PubMed Web of Science ®Google Scholar
• Ueno N T, Buzdar A U, Singletary F C. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol 1997; 40: 321–329
   PubMed Web of Science ®Google Scholar
• Swain S M, Lippman M E. Treatment of patient with inflammatory breast cancer. Important Adv Oncol, VT DeVita, Jr, S Hellman, SA Rosenberg. J.B. Lippincott Company, Philadelphia 1989; 129–150
   Google Scholar
• Kolaric K, Vukas D, Potrebica V. CAP (cyclophosphamide, adria-mycin, platinum) vs. FAC (5-fluorouracil, adriamycin cyclophosphamide) combination chemotherapy in metastatic breast cancer patients—a preliminary report. Proc Am Soc Clin Oncol 1986; 5: 299
   Google Scholar
• Jones A L, Smith I E, O'Brien M ER. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. J Clin Oncol 1994; 12: 1259–1265
   PubMed Web of Science ®Google Scholar
• Roth B J, Sledge G W, Williams S D. Methotrexate vinblastine, doxorubicin, and cisplatin (M-VAC) as first-line chemotherapy (CT) in metastatic breast cancer (MBC): a phase II trial of the Hoosier Oncology Group. Proc Am Soc Clin Oncol 1988; 7: 118
   Google Scholar
• Langer C J, Catalano R, Weiner L M. Phase II evaluation of methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) in advanced, measurable breast carcinoma. Cancer Invest 1995; 13: 150–159
   PubMed Web of Science ®Google Scholar
• Kudelka A, Abel W, Berken A. Phase II trial of methotrexate, vinblastine, doxorubicin, cisplatin and folinic acid (MVAC/ FA) in the treatment of locally advanced and metastatic breast cancer: an update. Proc Am Soc Clin Oncol 1989; 8: 194
   Google Scholar
• Jahnke L, Winter J. High-dose therapy's role in breast cancer management. Contemp Oncol 1993; 3: 38–49
   Google Scholar
• Peters W P. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer: yes [review]. Important Adv Oncol, VT DeVita, Jr, S Hellman, SA Rosenberg. J.B. Lippincott Company, Philadelphia 1995; 215–230
   Google Scholar
• Smith G A, Henderson I C. High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: the jury is still out [review]. Important Adv Oncol, VT DeVita, Jr, S Hellman, SA Rosenberg. J.B. Lippincott Company, Philadelphia 1995; 201–214
   Google Scholar